The present invention relates generally to medical/surgical devices and methods pertaining to treating heart disease, particularly heart failure. More specifically, the inventions described herein relate to devices and methods for reducing ventricular volume.
Described herein are devices, systems, and methods for improving cardiac function, and for reducing ventricular volume. Many of the devices and systems described herein reduce ventricular volume by partition the ventricle into productive and non-productive portions (e.g., by partially occluding a small portion of the ventricle).
Annually, heart failure leads to millions of hospital visits internationally. Heart failure (including congestive heart failure) is the description given to a myriad of symptoms that can be the result of the heart's inability to meet the body's demand for blood flow. In certain pathological conditions, the ventricles of the heart become ineffective in pumping the blood, causing a back-up of pressure in the vascular system behind the ventricle.
The reduced effectiveness of the heart is usually due to an enlargement of the heart. A myocardial ischemia may, for example, cause a portion of a myocardium of the heart to lose its ability to contract. Prolonged ischaemia can lead to infarction of a portion of the myocardium (heart muscle) wherein the heart muscle dies and becomes scar tissue. Once this tissue dies, it no longer functions as a muscle and cannot contribute to the pumping action of the heart. When the heart tissue is no longer pumping effectively, that portion of the myocardium is said to be hypokinetic, meaning that it is less contractile than the uncompromised myocardial tissue. As this situation worsens, the local area of compromised myocardium may in fact bulge out as the heart contracts, further decreasing the heart's ability to move blood forward. When local wall motion moves in this way, it is said to be dyskinetic, or akinetic. The dyskinetic portion of the myocardium may stretch and eventually form an aneurysmic bulge. Certain diseases may cause a global dilated myopathy, i.e., a general enlargement of the heart when this situation continues for an extended period of time.
As the heart begins to fail, distilling pressures increase, which stretches the ventricular chamber prior to contraction and greatly increases the pressure in the heart. In response, the heart tissue reforms to accommodate the chronically increased filling pressures, further increasing the work that the now comprised myocardium must perform.
Drug therapy typically treats the symptoms of the disease and may slow the progression of the disease, but it cannot cure the disease. One of the only permanent treatments for heart disease is heart transplantation, but heart transplant procedures are very risky, extremely invasive and expensive and are performed on a small percentage of patients. Many patient's do not qualify for heart transplant for failure to meet any one of a number of qualifying criteria, and, furthermore, there are not enough hearts available for transplant to meet the needs of heart failure patients who do qualify.
Substantial effort has been made to find alternative treatments for heart failure. For example, surgical procedures have been developed to dissect and remove weakened portions of the ventricular wall in order to reduce heart volume. This procedure is highly invasive, risky and expensive and is commonly only done in conjunction with other procedures (such as heart valve replacement or coronary artery by-pass graft). Additionally, the surgical treatment is usually only offered to the most severe class of patients and, accordingly, is not an option for most patients facing ineffective drug treatment. Finally, if the procedure fails, emergency heart transplant is the only presently available option.
Ventricular partitioning devices offer a solution for treating heart failure. Described herein are ventricular volume reduction device that may also act as ventricular partitioning devices. These devices generally function to partition a patient's ventricle into a productive region and a non-productive region. For such devices to function properly, they are positioned in a specific location within the patient's heart chamber. Delivery of a partitioning device may be made complicated by the anatomy of a patient and by aspects or characteristics of the delivery device or partitioning device itself. Thus, it would be beneficial to provide devices, systems and methods for delivering and deploying a partitioning device in a patient's ventricle.
Described herein are ventricular volume reduction devices and methods that may be implanted to reduce the volume of the ventricle in a safe and controlled manner.
Described herein are devices and systems including implants (which may be removable) and methods of using them for reducing ventricular volume. The implants described herein are cardiac implants that may be inserted into a patient's heart, particularly the left ventricle. The implant may support the heart wall, or may be secured to the heart wall. In some variations the implant is a ventricular partitioning device for partitioning the ventricle into productive and non-productive regions.
The ventricular volume reduction devices described herein may include a partitioning member (e.g., a membrane) and a frame for securing the membrane across the ventricle and/or for securing the device in the ventricle. In some variations the frame includes a plurality of individual (or connected) struts that are flexible and may collapse (for delivery) and expand (for securing in the ventricle). The struts may allow the device to flex/move in response to the motion of the heart.
In some variations, the device includes a partitioning member such as a membrane that is configured to span a mid- to lower-portion of a ventricle and to occlude a region of the ventricle (e.g., the apical region). Such devices may be adjustable (before, during or after implantation/insertion into the ventricle) to adjust the “height” of the membrane (e.g., the distance from the apex), and thereby adjust the remaining active volume in the ventricle. For example, in some variations the portion of the frame connected to the membrane may be adjusted to increase the distance from the partitioning member (e.g. membrane) and the base (e.g., foot or apical region) of the implant.
In some variations the device is configured so that the implant acts to assist with the pumping of the ventricle. For example, the device may include a contractible member (e.g., an inflatable member or balloon) that is in contact with the partitioning member to move it in a coordinated fashion with the motion of the heart walls, thereby assisting with the pumping of the ventricle. For example a balloon located in the region “behind” the implant (e.g., in the non-functional portion cut off by the partitioning member) may be cyclically inflated/deflated to assist with pumping. In other variations the balloon contacts the wall of the ventricle in this lower region, and translates the wall motion into motion of the partitioning member, to help with pumping.
In some variations the partitioning member is a membrane, as mentioned. This partitioning member may be configured so that it expands from a collapsed configuration to an expanded (ventricle-spanning) configuration. The ventricle-spanning configuration may be further adapted so that the surface is substantially smooth or free of irregularities. Such smooth surfaces may be preferable, since they may offer a lower risk of clot formation, for example, or for fluid dynamics considerations (e.g., decreasing turbulent flow). In some variations the partitioning membrane is formed of a plurality of overlapping members (e.g., leaves, etc.) that form the partitioning surface facing the active portion of the heart. For example, the parachute and fame may be constructed by cutting metal members (e.g., Nitinol) or relatively stiff, hard plastic members that may fan open or closed to expand/contract. In some variations, the membrane is formed of a relatively hard/stiff material (e.g., metal, thermoplastic, etc.) that is configured with hinged joints so that it may be collapsed for delivery and expanded once positioned. For example, the membrane may be formed of a relatively stiff material that folds along pre-determined edges. In other variations the partitioning member is a membrane that is secured to a frame (e.g., struts forming a membrane—supporting frame) only at the peripheral edge region of the partitioning member (e.g., membrane). This may allow the membrane to be held taut across the surface, rather than having the membrane to be anchored or secured more apically/distally relative to the rest of the implant.
In some variations the frame of the implant comprises a decoupled configuration including a partitioning member supporting frame and an anchoring frame. The anchoring frame and the membrane-supporting frame may comprise different (though connected) struts that are configured to expand from a delivery configuration into a deployed configuration. The struts may be formed or one or more shape memory alloy materials. In some variations, one or more of the struts forming the frame is a spiral strut, which changes shape in more than one plane. In some variations the struts forming the implant overlap in the center region (e.g., in the axial middle region of the implant). The overlapping region may further support the partitioning member, reducing the volume. In some variations the struts forming the frame include inner and outer strut regions (e.g., the struts double back on themselves). The inner and outer struts may be differentially connected to the partitioning member and configured to contact tissue.
Also described herein are implants including frames having one or more bridge struts. The bridge struts may couple adjacent struts to enhance the strength and/or durability of the struts once the device is in the implanted configuration.
“Tall” implants including a membrane and a support or strut region are also described. In such variations the struts (which may be arranged as spiral struts, described above, extend up from a foot or apical region to bend of nearly 90° (e.g., between 60° and 90°, between about 70° and 90°, between about 80° and 90°, etc.) the top region of the implant, to which the membrane is connected, may be substantially flat (formed of the upper half of the struts, to minimize the ventricular volume.
A ventricular volume reducing device may also include one or more struts that are hinged or otherwise configured to open/collapse the partitioning element (e.g., membrane). Thus, the device may include a frame that converts from an extended configuration (collapsed) in which distal and proximal strut regions are in the same plane, connected at respective distal and proximal ends, and arranged end-to-end. For example, in an umbrella-frame configuration, the struts may be deployed from this small-cross-sectional configuration by collapsing downward along the hinge region near the respective distal and proximal ends of the struts, thereby changing the angle between the distal and proximal struts from 180° to less than 90° (e.g., less than 45°, or between 10° and 45°, etc.). Converting the implant in this manner may arrange the partitioning member across the diameter of the ventricle to partition it, as mentioned above. The hinge region between the proximal and distal struts may also include one or more anchoring features (e.g., hooks, barbs, etc.).
Another variation of a ventricular volume reducing device include a frame comprising struts that expand from a common apex, wherein two struts are substantially parallel to each other. This may allow the membrane to be folded between the struts so that as it expands, membrane maybe held taught, preventing the formation of significant ‘pleat’ regions. Thus, the frame may include one or more struts that help manage the membrane. In this example, the membrane may be held taut on the face of the membrane facing the active ventricle region. This variation may be referred to as “scissor struts.”
Also described herein are ventricular volume reduction devices which do not include a “foot” region, but mechanically expand within the ventricle to contact the walls of the ventricle only from the sides (rather than the apex). For example, such a footless configuration may include an upper and lower frame that both include membranes and have radially extending struts that all terminate in anchors.
Although many of the variations described herein include struts formed of a flexible material such as a metal (e.g., Nitinol, stainless steel, etc.) or a plastic (e.g., thermoplastic), the struts may, in some variations, be inflatable struts. Inflatable struts may be formed of laminated layers (sealed) of material (including the membrane material) that are inflated with a fluid (e.g., gas, liquid, etc.) or hardenable resin/epoxy upon insertion into the ventricle.
In some variations the ventricular partitioning device may be configured to include one or more visualizable (e.g., under fluoroscopy, ultrasound, etc.) element. For example, the device may include a single strut that is configured to be visualized (e.g., coated with or formed by a radioopaque material). Such variations may be particularly useful for asymmetric devices. In some variations more than one strut may be marked for visualization. In some variations, the device may be marked with an oriented marker (e.g., an asymmetric shape) allowing better resolution of the three-dimensional orientation of the device even in a 2D fluoroscopic image. In some variations the device may be marked with words, phrases, images, icons, or the like.
A ventricular partitioning device may also include self-tapping struts that are configured to expand and rotate or otherwise drive themselves into the ventricular wall upon implantation. In one variation the implant includes spiral-cut or formed struts that expand towards the wall of the ventricle while driving the foot region (or lower region) of the implant towards the apex of the heart.
Any of the strut variations described herein may be formed of two or more layers of material (e.g., formed by cutting two abutting layers of thin Nitinol material, such as two concentrically arranged tubes). The thin material may be cut to form two (or more) layers of struts. These struts may have different thicknesses. Processing may be improved by providing multiple relatively thin layers of near-overlapping material to form the struts, rather than a single thick layer (having an equivalent thickness to the multiple thin layers).
In variations of the ventricular volume reducing devices described herein including a membrane (and particularly a flexible membrane), the membrane may be advantageously secured to the frame (e.g., struts) in various ways. For example, in some variations the membrane is secured to the frame by including eyelet regions (e.g., pre-formed concavities) on the struts to provide a bonding region. Each strut may include one or more such regions.
In some variations, the membrane of the implant may be formed directly onto the struts by dip coating. For example, the frame (in an expanded configuration) may be applied to a polished mandrel and used to dip coat into a polymer solution that will harden on the mandrel, and be attached to the frame. Multiple dip coatings (with or without the mandrel) may be performed.
The membrane may be formed of different materials, or may have different regions that have different or complementary properties. For example, the implant may include an outer membrane formed of a membrane (e.g., ePTFE) that is optimized for tissue in-growth, while the inner membrane (facing the non-functional portion of the ventricle when implanted) may be optimized for hydraulic load (e.g., creep resistance).
In some variations the membrane may encapsulate or surround portions of the device. For example, the edge of the membrane may be laminated back on itself to enclose or partially enclose a support element, a collapse element or the like (e.g., a string or suture). In some variations the different radial sections of the membrane may be separated by spacers to aid deployment. For example, the edge or rim region may include a metal or elastic polymer that helps the membrane fully deploy during operation. This spacer may also help seal the membrane to the wall of the ventricle, and may prevent the membrane from sticking to itself when the device is expanded from the collapsed configuration.
Generally, the membrane may be formed or secured to the implant frame (or struts) in a pre-loaded configuration. For example, although the implant frame may be configured to expand to a fully expanded configuration (having a maximum diameter) of 100%, the membrane may be attached when the frame (or individual struts of the frame) are only partially expanded (e.g., 90%, 85%, 80%, 75%, 70%, etc. expanded). This may also be referred to as preloading the frame. Since the membrane is slightly elastic, the load (expansion force) applied by the frame when implanted into the ventricle may allow it to expand slightly. In this manner, the membrane may be laminated in nearly the size (or slightly larger than the size) of the implanted device.
In variations of the devices including a foot region that is configured to contact the wall (e.g., apical region) of the ventricle, the tissue-contacting regions may be configured of a softer polymer (e.g., having a lower durometer) than the rest of the foot and/or hub. In some variations the foot region may be inverted or invertable, so that it does not prevent the frame or a portion of the frame from getting as close as possible to the wall of the ventricle.
In some variations, the device ventricular volume reduction device includes one or more conical, self-expanding structures configured to be inserted into the apex of the ventricle to reduce the volume of the ventricle. This variation of the implant may be inflatable. This variation, may or may not include an additional partitioning membrane, such as a membrane spanning the top portion of the device (e.g., facing away from the apex of the ventricle when inserted). This variation may also not include a separate frame as described in many of the device variations above.
Also described herein are stacking devices that may be used either to reduce ventricular volume, or to protect from myocardial infarction.
All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
In general, described herein are implant for insertion into a patient's ventricle (e.g., left ventricle) to reduce ventricular volume by partitioning the ventricle into a productive and a non-productive portion. In some variations of these implants, a partitioning element, which may be a surface, extends at least partially across the diameter of the ventricle to partition the ventricle and thereby reduce the volume. In some variations the partitioning element is a membrane, which may be flexible. One or more supports may be used to support the membrane. An implant may also include one or more struts that can expand and collapse as necessary, and may span the diameter of the ventricle to position and/or anchor the partitioning element across the ventricle. In general, these implants may be delivered in a low-profile collapsed configuration and expanded in the ventricle to reduce the volume of the ventricle.
For example, in some variations the implants include a partitioning element, and plurality of struts that may be expanded from a collapsed configuration into an expanded configuration in which the partitioning element (e.g., membrane) is extended and anchored across the ventricle to reduce ventricular volume. The implant may also include a hub (e.g., a central hub) from which the plurality of struts extends. In some variations the implant include a foot extending from the hub of the implant; the foot region and the hub may be separated by a body region. The body region therefore set the “height” of the implant from the foot to the partitioning element. In general, the foot region may be an atraumatic foot that is configured to rest against the surface of the heart (e.g., the ventricle). In some variations the foot region may act as an anchor that penetrates the heart and helps secure the implant in position.
In general, the implant may be anchored or otherwise secured across the ventricle to reduce ventricular volume. Thus, the implant may include one or more (or an array of) anchors for securing the implant in position within the ventricle, preferably within the apical region of the ventricle. In some variations the outer edge or edges of the partitioning element include one or more tissue penetrating elements that help anchor the implant in position. For example, the end of the struts supporting a partitioning element (e.g., membrane) may be configured as tissue-penetrating barbs, hooks, or the like. These ends regions may penetrate the ventricular wall (even just slightly) to secure the implant within the ventricle.
In some variations the edge of the partitioning element is configured to seal against the wall of the ventricle. A seal may be formed with the wall by any appropriate means, including adhesive means (using a biocompatible adhesive), inflatable means, swellable means, pressure-applying means, or the like.
It may be desirable to adjust or control the size of the region the ventricle portioned, and therefore the amount of volume reduction in the ventricle, by controlling the size and dimension of the implant. For example, in the variations of implants illustrated in
For example,
The height of this implant may be adjusted by sliding the collar 107 towards the proximal end, as shown in
The upper 201 (and in some variations lower) struts may be coupled to the membrane 203 forming the partitioning element. For example, the membrane may be formed of ePTFE or other flexible material; in other variation the membrane is a mesh or webbing. In some variations the membranes used herein are impermeable. In still other variations, the partitioning element is formed of stiff and/or rigid materials.
The post/stud element 209 may include a lumen or passage 223 through which one or more components of the delivery device may engage. The outer surface of the post/stud element may also be configured to allow secure locking of the collar by the locking mechanism. For example, the outer surface of the post may include notches, ridges, holes, or the like for the locking mechanism to engage. The implant may also optionally include a foot element 217 at the distal end.
Any of the variations of the implants described herein may also be configured as pumping assist implants, which (in addition to reducing ventricular volume) may actively or passively aid in ventricular pumping. For example,
In this variation, the pumping assistance element 307 within the assembly is captured between the frame and the positioning membrane. The balloon may be further equipped with an inflation/deflation port (not shown); the balloon port may communicate with an inflation/deflation source (e.g., outside of the ventricle) that may assist with pumping. The location of the balloon may allow the forces on the membrane to be transmitted to the frame of the device rather than the damage apical region of a patient's heart.
The pumping assistance element may function in two or more different modes. For example, the pumping assistance element may be actively inflated/deflated in coordination with the ventricle contraction; thus the pumping assistance element may be able to effect maximum upward deflection of the membrane, which in turn prompts enhanced ejection of the blood. In a second mode, the pumping assistance element may be let filled to a fixed volume. In this mode, the pumping action of the heart compresses the frame, and causes the membrane to deflect, passively assisting with pumping, as illustrated in
Another variation of a pumping assistance element in an implant 401 for decreasing ventricular volume is shown in
Although the majority of the implant variations described herein include a membrane as illustrated above, which may be made from a flexible material (e.g., ePTFE or other appropriate material), in some variations it may be desirable to have the partitioning element made of a more self-supporting material. Thus, in some variations a separate support frame may not be necessary. The frame generally provides support of the partitioning element (and anchoring of the device in the ventricle). In some variations the partitioning element is made more rigid so that an addition support (e.g., from the frame) is not necessary, though it may still be included.
In some variations the struts to which the partitioning member are secured are also used to anchor the implant within the ventricle. In some variations, it may also e beneficial to separate or additionally include struts that do not support the partitioning member, but that help anchor the implant. For example,
It may also be beneficial to include one or more members for supporting the partitioning element (e.g., membrane) from within the device. For example, one or more specialized struts may be configured to assume a supporting shape beneath the membrane to help maintain the membrane in a somewhat ‘flat’ or more volume-reducing configuration.
In
In
In some variations of the implants described herein it may also be desirable to include one or more bridges between struts in the implant. For example,
In any of the devices described herein, the partitioning element may be a membrane or surface (which may be flexible) that is coupled to struts. When the implant is in the collapsed configuration the partitioning element may be folded or collapsed around the struts so that the profile of the implant is sufficiently small. For example,
Any of the variations described herein may also include one or more locating struts which is visualizable (e.g., under fluoroscopy). Asymmetric implants (e.g., having one side that is shorter than another) may particularly benefit from locating struts, which may help orient the implant within the body. For example, one or more struts could be configured to be extended from the delivery system before the others. One or more of the struts could be treated to increase the radiopacity, e.g., by gold plating. Once exposed, the locating strut or struts could be used to orient the implant. For example, the locating strut could be placed at the papillary muscle so that the short side of the implant (in an asymmetric implant) falls at the papillary muscle. In general, the implant may be marked for visualization.
In some variations of the devices described herein the implant is formed from a plurality of tubes that are concentrically arranged and then cut (e.g., laser cut) to form the frame. This may allow relatively thinner struts to be formed compared to single-tube constructions. For example,
In many of the variations described herein the partitioning element is a membrane formed of a material such as ePTFE which is secured to one or more region of the struts. Binding of the material such as ePTFE to the metal (e.g., Nitinol) struts may be a challenge. In some variations, the binding to the end regions of the struts is enhanced by providing cut-out regions in the strut that allow thicker bonding regions. This is illustrated in
In general, in variations in which the membrane is formed by laminating or heat-securing a flat layer of material to a wire frame (e.g., Nitinol), the membrane may be cut out of a sheet of material. For example, in some variations the frame may be sandwiched between two layers of material having different properties. In one variation the outer layer of material forming the partitioning element is a sheet of ePTFE that is optimized for tissue in-growth and the inner layer of material forming the partitioning element is a sheet of ePTFE optimized for hydraulic load (e.g., having a high creep resistance). Thus, the ePTFE facing the active region of the ventricle is configured to tissue in-growth, while the region facing the static chamber is optimized for hydraulic loading, providing a fluid barrier and resistance to creed effects caused by long-term loading.
Alternatively, in some variations the membrane may be formed on the implant by dip coating the frame 2001 after it has been connected to a polished mandrel 2003, as illustrated in
Any of the variations described herein may also be retrievable, and may be configured for use with a retrieving element. For example,
In operation, an implant may be removed after collapsing the implant (e.g., by pulling on a string or other element configured to collapse the expanded implant) by drawing the implant against the distal tip of the prolapsing guide catheter, allowing the distal end of the catheter to collapse around the proximal end of the collapsed implant, as shown in
Another variation of an implant retrieval device is shown in
In some variations, the ventricular volume reduction implant may be adapted to include a removal element that facilitates removal of the implant after insertion. For example,
Other device and system for removal of an implanted device, or for “bailout” (stopping and removing a device during the insertion procedure) are also contemplated. For example, an implant may include a suture or ring (e.g., a Nitinol ring) around the outer perimeter as previously described. A removal device may include a hook or grasper for engaging the ring or suture to constrict the outer rim of the device, collapsing it back into the condensed form.
In general, before insertion of an implant into a ventricle, the practitioner (e.g., surgeon) may determine what size implant would best work in the ventricle to appropriately reduce the ventricular volume. Thus, one or more sizers or sizing techniques may be used. In some variation, sizing of the implant is performed using analysis of angiographic and/or other imaging techniques such as ultrasound. Visualization data may then be used to identify the height and diameter of the implantation zone within the ventricle and therefore the proper size and/or shape of the implant to be used. In performing this step, it would be useful to have one or more sizers that could be used to provide reference when examining the heart to determine the orientation, size and morphology of the implant to be used to reduce ventricular volume.
In one variation, a sizer device comprises an expandable frame (similar to the implant frames described above) having a plurality of radiopaque bands or other markers for visualization of the outer perimeter of the sizer.
In some variation of the sizer describe above, the sizer expansion is limited by cross-struts 2609 to prevent over expansion within the ventricle, as shown in
In some variations, the sizer is configured so that expansion and collapse are controlled by controlling the proximal and distal ends of the expandable region, as shown by
Rotation of the sizer may be particularly helpful for determining the location of structures like chords that extend across region of the ventricle, but are not typically visible under most visualization techniques.
In some variations the sizer is per-biased or shape-set into the expanded form. For example, the sizer may be shape-set into a rounded form as shown in
In
In some variations, the sizer may include a separate or integral depth measuring element. For example,
Although the methods and systems described above may include a separate sizer to be used prior to implantation of the ventricular volume reduction implant, in some variations the implant may include an integral sizer. For example, the distal tip of the implant may include a sizer that is configured to be used prior to fully deploying the implant. In one variation a sizer balloon at the distal tip region (the “foot region”) of an implant may be inflated to determine (by contact with ventricle wall and landing zone) the configuration of the ventricular landing zone prior to fully deploying the implant. The balloon may be filled with a radiopaque material.
In general, the implants described herein may be flushed with fluid (e.g., saline) prior to implantation, and bubbles (air bubbles) may be removed. It may be desired to flush the device in an end-to-end rather than from a port in the middle of the sleeve. One difficult area to flush is the inside of the implant near the balloon. This region may be flushed by including a temporary or permanent flush port to the center of the implant, as illustrated in
In some variations, the implant is loaded in to a sleeve, as mentioned. For example,
In variations in which the delivery device includes a balloon (e.g., to help expand the implant when inserted into the ventricle) or where the implant itself includes a balloon (e.g., as a foot region, strut, etc.), the balloon may be pre-filled with inflation fluid. This may avoid bubbles or filling irregularities. For example, in variations of devices and system including balloons, the implant may include a “prep port” that can be opened on one region of the inflatable member, from which fluid (e.g., saline) may be drawn.
With the implant 3607 collapsed inside the implant loader 3606, the implant loader can be attached to the proximal portion of a guide catheter handle 3604, as shown in
In some variations, the guide catheter handle may be configured so that the valve 3602 is used to route the flow of the side port 3603 distal or proximal of the valve. This may allow the side port to perform different functions. For example, as shown in
While particular forms of the invention have been illustrated and described herein, it will be apparent that various modifications and improvements can be made to the invention. Moreover, individual features of embodiments of the invention may be shown in some drawings and not in others, but those skilled in the art will recognize that individual features of one embodiment of the invention can be combined with any or all the features of another embodiment. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated. It is intended that this invention to be defined by the scope of the appended claims as broadly as the prior art will permit.
This application claims priority to U.S. Provisional Patent Application Ser. No. 61/255,018, filed on Oct. 26, 2009, titled “VENTRICULAR VOLUME REDUCTION,” which is herein incorporated by reference in its entirety. The devices and methods described herein may be applied to many of the devices and systems described in any of the references listed below. In particular, these references generally describe devices, systems, and methods for improving cardiac function and to ventricular partitioning devices in particular. Thus, the following patents/patent applications are herein incorporated by reference in their entirety: U.S. patent application Ser. No. 09/635,511, titled “DEVICE AND METHOD FOR TREATMENT OF HOLLOW ORGANS,” filed on Aug. 9, 2000; U.S. patent application Ser. No. 10/212,032, titled “METHOD FOR IMPROVING CARDIAC FUNCTION,” filed on Aug. 1, 2002; U.S. patent application Ser. No. 10/212,033, titled “DEVICE FOR IMPROVING CARDIAC FUNCTION,” filed on Aug. 1, 2002; U.S. patent application Ser. No. 10/302,269, titled “DEVICE WITH A POROUS MEMBRANE FOR IMPROVING CARDIAC FUNCTION,” filed on Nov. 22, 2002; U.S. patent application Ser. No. 10/302,272, titled “METHOD OF IMPROVING CARDIAC FUNCTION USING A POROUS MEMBRANE,” filed on Nov. 22, 2002; U.S. patent application Ser. No. 10/382,962, titled “METHOD FOR IMPROVING CARDIAC FUNCTION,” filed on Mar. 6, 2003; U.S. patent application Ser. No. 10/436,959, titled “SYSTEM FOR IMPROVING CARDIAC FUNCTION,” filed on May 12, 2003; U.S. patent application Ser. No. 10/754,182, titled “VENTRICULAR PARTITIONING DEVICE,” filed on Jan. 9, 2004; U.S. patent application Ser. No. 10/791,916, titled “INFLATABLE VENTRICULAR PARTITIONING DEVICE,” filed on Mar. 3, 2004; U.S. patent application Ser. No. 10/913,608, titled “VENTRICULAR PARTITIONING DEVICE,” filed on Aug. 5, 2004; U.S. patent application Ser. No. 11/151,156, titled “MULTIPLE PARTITIONING DEVICES FOR HEART TREATMENT,” filed on Jun. 10, 2005; U.S. patent application Ser. No. 11/151,164, titled “PERIPHERAL SEAL FOR A VENTRICULAR PARTITIONING DEVICE,” filed on Jun. 10, 2005; U.S. patent application Ser. No. 11/199,633, titled “METHOD FOR TREATING MYOCARDIAL RUPTURE,” filed on May 9, 2005; U.S. patent application Ser. No. 11/640,469, titled “CARDIAC DEVICE AND METHODS OF USE THEREOF,” filed on Dec. 14, 2006; U.S. patent application Ser. No. 11/800,998, titled “SYSTEM FOR IMPROVING CARDIAC FUNCTION,” filed on May 7, 2007; U.S. patent application Ser. No. 11/801,075, titled “SYSTEM FOR IMPROVING CARDIAC FUNCTION,” filed on May 7, 2007; U.S. patent application Ser. No. 11/860,438, titled “LAMINAR VENTRICULAR PARTITIONING DEVICE,” filed on Sep. 24, 2007; U.S. patent application Ser. No. 12/125,015, titled “VENTRICULAR PARTITIONING DEVICE,” filed on May 21, 2008; U.S. patent application Ser. No. 12/129,443, titled “THERAPEUTIC METHODS AND DEVICES FOLLOWING MYOCARDIAL INFARCTION,” filed on May 29, 2008; U.S. patent application Ser. No. 12/181,282, titled “INFLATABLE VENTRICULAR PARTITIONING DEVICE,” filed on Jul. 28, 2008; U.S. patent application Ser. No. 12/198,010, titled “RETRIEVABLE DEVICES FOR IMPROVING CARDIAC FUNCTION,” filed on Aug. 25, 2008; U.S. patent application Ser. No. 12/198,022, titled “RETRIEVABLE CARDIAC DEVICES,” filed on Aug. 25, 2008; and U.S. patent application Ser. No. 12/268,346, titled “SYSTEM FOR IMPROVING CARDIAC FUNCTION,” filed on Nov. 10, 2008.
Number | Name | Date | Kind |
---|---|---|---|
3874388 | King et al. | Apr 1975 | A |
4007743 | Blake | Feb 1977 | A |
4425908 | Simon | Jan 1984 | A |
4453545 | Inoue | Jun 1984 | A |
4536893 | Parravicini | Aug 1985 | A |
4588404 | Lapeyre | May 1986 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4685446 | Choy | Aug 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4819751 | Shimada et al. | Apr 1989 | A |
4832055 | Palestrant | May 1989 | A |
4917089 | Sideris | Apr 1990 | A |
4983165 | Loiterman | Jan 1991 | A |
5104399 | Lazarus | Apr 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5192314 | Daskalakis | Mar 1993 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5385156 | Oliva | Jan 1995 | A |
5389087 | Miraki | Feb 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5496277 | Termin et al. | Mar 1996 | A |
5527337 | Stack et al. | Jun 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5549621 | Bessler et al. | Aug 1996 | A |
5551435 | Sramek | Sep 1996 | A |
5578069 | Miner, II | Nov 1996 | A |
5634936 | Linden et al. | Jun 1997 | A |
5634942 | Chevillon et al. | Jun 1997 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5702343 | Alferness | Dec 1997 | A |
5709707 | Lock et al. | Jan 1998 | A |
5758664 | Campbell et al. | Jun 1998 | A |
5791231 | Cohn et al. | Aug 1998 | A |
5797849 | Vesely et al. | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5800457 | Gelbfish | Sep 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5833698 | Hinchliffe et al. | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5843170 | Ahn | Dec 1998 | A |
5860951 | Eggers et al. | Jan 1999 | A |
5861003 | Latson et al. | Jan 1999 | A |
5865730 | Fox et al. | Feb 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5871017 | Mayer | Feb 1999 | A |
5875782 | Ferrari et al. | Mar 1999 | A |
5876325 | Mizuno et al. | Mar 1999 | A |
5876449 | Starck et al. | Mar 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5882340 | Yoon | Mar 1999 | A |
5910150 | Saadat | Jun 1999 | A |
5916145 | Chu et al. | Jun 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5925062 | Purdy | Jul 1999 | A |
5925076 | Inoue | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
5961539 | Northrup, III et al. | Oct 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
6024096 | Buckberg | Feb 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6045497 | Schweich, Jr. et al. | Apr 2000 | A |
6059715 | Schweich, Jr. et al. | May 2000 | A |
6076013 | Brennan et al. | Jun 2000 | A |
6077214 | Mortier et al. | Jun 2000 | A |
6077218 | Alferness | Jun 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6095968 | Snyders | Aug 2000 | A |
6096347 | Geddes et al. | Aug 2000 | A |
6099832 | Mickle et al. | Aug 2000 | A |
6102887 | Altman | Aug 2000 | A |
6125852 | Stevens et al. | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6155968 | Wilk | Dec 2000 | A |
6156027 | West | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6193731 | Oppelt et al. | Feb 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6221104 | Buckberg et al. | Apr 2001 | B1 |
6230714 | Alferness et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6258021 | Wilk | Jul 2001 | B1 |
6267772 | Mulhauser et al. | Jul 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6296656 | Bolduc et al. | Oct 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6343605 | Lafontaine | Feb 2002 | B1 |
6348068 | Campbell et al. | Feb 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6360749 | Jayaraman | Mar 2002 | B1 |
6364896 | Addis | Apr 2002 | B1 |
6387042 | Herrero | May 2002 | B1 |
6406420 | McCarthy et al. | Jun 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6450171 | Buckberg et al. | Sep 2002 | B1 |
6482146 | Alferness et al. | Nov 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6508756 | Kung et al. | Jan 2003 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6537198 | Vidlund et al. | Mar 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6572643 | Gharibadeh | Jun 2003 | B1 |
6586414 | Haque et al. | Jul 2003 | B2 |
6592608 | Fisher et al. | Jul 2003 | B2 |
6613013 | Haarala et al. | Sep 2003 | B2 |
6622730 | Ekvall et al. | Sep 2003 | B2 |
6645199 | Jenkins et al. | Nov 2003 | B1 |
6652555 | Van Tassel et al. | Nov 2003 | B1 |
6681773 | Murphy et al. | Jan 2004 | B2 |
6685627 | Jayaraman | Feb 2004 | B2 |
6702763 | Murphy et al. | Mar 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6776754 | Wilk | Aug 2004 | B1 |
6852076 | Nikolic et al. | Feb 2005 | B2 |
6887192 | Whayne et al. | May 2005 | B1 |
6951534 | Girard et al. | Oct 2005 | B2 |
6959711 | Murphy et al. | Nov 2005 | B2 |
6994093 | Murphy et al. | Feb 2006 | B2 |
7144363 | Pai et al. | Dec 2006 | B2 |
7172551 | Leasure | Feb 2007 | B2 |
7320665 | Vijay | Jan 2008 | B2 |
7399271 | Khairkhahan et al. | Jul 2008 | B2 |
7485088 | Murphy et al. | Feb 2009 | B2 |
7569062 | Kuehn et al. | Aug 2009 | B1 |
7582051 | Khairkhahan et al. | Sep 2009 | B2 |
7674222 | Nikolic et al. | Mar 2010 | B2 |
7762943 | Khairkhahan | Jul 2010 | B2 |
7862500 | Sharkey et al. | Jan 2011 | B2 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20020019580 | Lau et al. | Feb 2002 | A1 |
20020026092 | Buckberg et al. | Feb 2002 | A1 |
20020028981 | Lau et al. | Mar 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020055767 | Forde et al. | May 2002 | A1 |
20020055775 | Carpentier et al. | May 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020133227 | Murphy et al. | Sep 2002 | A1 |
20020161392 | Dubrul | Oct 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020169359 | McCarthy et al. | Nov 2002 | A1 |
20020169360 | Taylor et al. | Nov 2002 | A1 |
20020183604 | Gowda et al. | Dec 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20030045896 | Murphy et al. | Mar 2003 | A1 |
20030050682 | Sharkey et al. | Mar 2003 | A1 |
20030050685 | Nikolic et al. | Mar 2003 | A1 |
20030078671 | Lesniak et al. | Apr 2003 | A1 |
20030105384 | Sharkey et al. | Jun 2003 | A1 |
20030109770 | Sharkey et al. | Jun 2003 | A1 |
20030120337 | Van Tassel et al. | Jun 2003 | A1 |
20030135230 | Massey et al. | Jul 2003 | A1 |
20030149333 | Alferness | Aug 2003 | A1 |
20030149422 | Muller | Aug 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20040002626 | Feld et al. | Jan 2004 | A1 |
20040034366 | van der Burg et al. | Feb 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040054394 | Lee | Mar 2004 | A1 |
20040064014 | Melvin et al. | Apr 2004 | A1 |
20040122090 | Lipton | Jun 2004 | A1 |
20040127935 | Van Tassel et al. | Jul 2004 | A1 |
20040133062 | Pai et al. | Jul 2004 | A1 |
20040136992 | Burton et al. | Jul 2004 | A1 |
20040172042 | Suon et al. | Sep 2004 | A1 |
20040186511 | Stephens et al. | Sep 2004 | A1 |
20040215230 | Frazier et al. | Oct 2004 | A1 |
20040260331 | D'Aquanni et al. | Dec 2004 | A1 |
20040260346 | Overall et al. | Dec 2004 | A1 |
20040267086 | Anstadt et al. | Dec 2004 | A1 |
20040267378 | Gazi et al. | Dec 2004 | A1 |
20050007031 | Hyder | Jan 2005 | A1 |
20050015109 | Lichtenstein | Jan 2005 | A1 |
20050038470 | van der Burg et al. | Feb 2005 | A1 |
20050043708 | Gleeson et al. | Feb 2005 | A1 |
20050065548 | Marino et al. | Mar 2005 | A1 |
20050085826 | Nair et al. | Apr 2005 | A1 |
20050096498 | Houser et al. | May 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050124849 | Barbut et al. | Jun 2005 | A1 |
20050137690 | Salahieh et al. | Jun 2005 | A1 |
20050142180 | Bisgaier et al. | Jun 2005 | A1 |
20050177180 | Kaganov et al. | Aug 2005 | A1 |
20050187620 | Pai et al. | Aug 2005 | A1 |
20050216052 | Mazzocchi et al. | Sep 2005 | A1 |
20050228434 | Amplatz et al. | Oct 2005 | A1 |
20050277981 | Maahs et al. | Dec 2005 | A1 |
20050277983 | Saadat et al. | Dec 2005 | A1 |
20050283218 | Williams | Dec 2005 | A1 |
20060019888 | Zhou | Jan 2006 | A1 |
20060025800 | Suresh | Feb 2006 | A1 |
20060030881 | Sharkey et al. | Feb 2006 | A1 |
20060063970 | Raman et al. | Mar 2006 | A1 |
20060069430 | Rahdert et al. | Mar 2006 | A9 |
20060079736 | Chin et al. | Apr 2006 | A1 |
20060116692 | Ward | Jun 2006 | A1 |
20060199995 | Vijay | Sep 2006 | A1 |
20060229491 | Sharkey et al. | Oct 2006 | A1 |
20060259124 | Matsuoka et al. | Nov 2006 | A1 |
20060264980 | Khairkhahan et al. | Nov 2006 | A1 |
20060276684 | Speziali | Dec 2006 | A1 |
20070129753 | Quinn et al. | Jun 2007 | A1 |
20070135889 | Moore et al. | Jun 2007 | A1 |
20070162048 | Quinn et al. | Jul 2007 | A1 |
20070213578 | Khairkhahan et al. | Sep 2007 | A1 |
20070213815 | Khairkhahan et al. | Sep 2007 | A1 |
20080015717 | Griffin et al. | Jan 2008 | A1 |
20080045778 | Lichtenstein et al. | Feb 2008 | A1 |
20080071298 | Khairkhahan et al. | Mar 2008 | A1 |
20080228805 | Bruck et al. | Sep 2008 | A1 |
20080293996 | Evans et al. | Nov 2008 | A1 |
20080319254 | Nikolic et al. | Dec 2008 | A1 |
20090054723 | Khairkhahan et al. | Feb 2009 | A1 |
20090062601 | Khairkhahan et al. | Mar 2009 | A1 |
20090187063 | Khairkhahan | Jul 2009 | A1 |
20090254195 | Khairkhahan et al. | Oct 2009 | A1 |
20090287040 | Khairkhahan et al. | Nov 2009 | A1 |
20100048987 | Khairkhahan et al. | Feb 2010 | A1 |
20100121132 | Nikolic et al. | May 2010 | A1 |
20100262168 | Khairkhahan et al. | Oct 2010 | A1 |
20100274227 | Khairkhahan et al. | Oct 2010 | A1 |
20110178362 | Evans et al. | Jul 2011 | A1 |
20120259356 | Khairkhahan | Oct 2012 | A1 |
20130090677 | Evans et al. | Apr 2013 | A1 |
20130165735 | Khairkhahan et al. | Jun 2013 | A1 |
20130317537 | Khairkhahan | Nov 2013 | A1 |
20130338695 | Nikolic et al. | Dec 2013 | A1 |
Number | Date | Country |
---|---|---|
H08257031 | Oct 1996 | JP |
2003512128 | Apr 2003 | JP |
2003512129 | Apr 2003 | JP |
WO 9637859 | Nov 1996 | WO |
WO 9803213 | Jan 1998 | WO |
WO 0027292 | May 2000 | WO |
WO 0042919 | Jul 2000 | WO |
WO 0050639 | Aug 2000 | WO |
WO 0130266 | May 2001 | WO |
WO 0178625 | Oct 2001 | WO |
WO 0230335 | Apr 2002 | WO |
WO 0245710 | Jun 2002 | WO |
WO 02071977 | Sep 2002 | WO |
WO 02087481 | Nov 2002 | WO |
WO 03007778 | Jan 2003 | WO |
WO 03043507 | May 2003 | WO |
WO 03073961 | Sep 2003 | WO |
WO 03090716 | Nov 2003 | WO |
WO 03099300 | Dec 2003 | WO |
WO 03099320 | Dec 2003 | WO |
WO 03103538 | Dec 2003 | WO |
WO 03103743 | Dec 2003 | WO |
WO 2004012629 | Feb 2004 | WO |
WO 2004019866 | Mar 2004 | WO |
WO 2004066805 | Aug 2004 | WO |
WO 2004100803 | Nov 2004 | WO |
WO 2005007031 | Jan 2005 | WO |
WO 2005007873 | Jan 2005 | WO |
WO 2005041745 | May 2005 | WO |
WO 2005091860 | Oct 2005 | WO |
WO 2005102181 | Nov 2005 | WO |
WO 2006033107 | Mar 2006 | WO |
WO 2007092354 | Aug 2007 | WO |
Entry |
---|
Khairkhahan Alexander; U.S. Appl. No. 13/129,961 entitled “Devices and methods for delivering an endocardial device,” filed Jul. 14, 2011. |
Boersma et al.; Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour; Lancet: vol. 348; pp. 771-775; 1996. |
Sharkey et al.; Left ventricular apex occluder. Description of a a ventricular partitioning device; Eurolnterv.; 2(1); pp. 125-127; May 2006. |
U.S. Food & Drug Administration; AneuRx Stent Graft System—Instructions for use; (pre-market approval); Sep. 29, 1999; downloaded Apr. 25, 2013 (http://www.accessdata.fda.gov/cdrh—docs/pdf/P990020c.pdf). |
Alexander, Miles; U.S. Appl. No. 13/827,927 entitled “Systems and methods for making a laminar ventricular partitioning device,” filed Mar. 14, 2013. |
Kermode et al.; U.S. Appl. No. 13/828,184 entitled “Devices and methods for delivering an endocardial device,” filed Mar. 14, 2013. |
AGA Medical Corporation. www.amplatzer.com/products. “The Muscular VSD Occluder” and “The Septal Occluder” device description. Accessed Apr. 3, 2002. |
Artrip et al.; Left ventricular volume reduction surgery for heart failure: A physiologic perspective; J Thorac Cardiovasc Surg; vol. 122; No. 4; pp. 775-782; 2001. |
Di Mattia, et al. Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functioal results. European Journal of Cardio-thoracic Surgery. 1999; 15:413-418. |
Dor, et al. Ventricular remodeling in coronary artery disease. Current Opinion in Cardiology. 1997; 12:533-537. |
Dor, V. The treatment of refractory ischemic ventricular tachycardia by endoventricular patch plasty reconstruction of the left ventricle. Seminars in Thoracic and Cardiovascular Surgery. 1997; 9(2): 146-155. |
Dor. Surgery for left ventricular aneurysm. Current Opinion in Cardiology. 1990; 5: 773-780. |
Gore Medical. www.goremedical.com. “Helex Septal Occluder” product description. Accessed Apr. 3, 2002. |
Januzzi, James L.; Natriuretic peptide testing: A window into the diagnosis and prognosis of heart failure; Cleveland Clinic Journal of Medicine; vol. 73; No. 2; pp. 149-152 and 155-157; Feb. 2006. |
Katsumata, et al. An objective appraisal of partial left ventriculectomy for heart failure. Journal of Congestive Heart Failure and Circulator Support. 1999; 1(2): 97-106. |
Kawata, et al. Systolic and Diastolic Function after Patch Reconstruction of Left Ventricular Aneurysms. Ann. Thorac. Surg. 1995; 59:403-407. |
James et al.; Blood Volume and Brain Natriuretic Peptide in Congestive Heart Failure: A Pilot Study; American Heart Journal; vol. 150; issue 5, pp. 984.e1-984.e6 (abstract); Dec. 6, 2005. |
Boutillette et al.; U.S. Appl. No. 12/893,832 entitled “Devices and methods for delivering an endocardial device,” filed Sep. 29, 2010. |
Number | Date | Country | |
---|---|---|---|
20110098525 A1 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
61255018 | Oct 2009 | US |